Substantial changes in the management of cancer patients have been required worldwide in response to the COVID-19 pandemic. Beyond the due details on the primitive cancer site and setting at diagnosis, these latter adaptions are most commonly exemplified by a significant reduction in the screening of asymptomatic subjects, delays in elective surgery and radiotherapy for primary tumors, and dose reductions and/or delays in systemic therapy administration. Advanced breast cancer patients with hormonal receptor positive, HER2 negative tumors are usually treated with endocrine therapy combined with CDK 4/6 inhibitors as first- and second-line treatment. During the pandemic, experts’ recommendations have suggested the omission or delay of CDK 4/6 inhibitors delivery, or a careful evaluation of their real need due to the hypothesized increased risk of SARS-Cov-2 infection and disease possibly related to neutropenia. The inherent literature is sparse and inconsistent. We herein present data on the use of CDK 4/6 inhibitors during the pandemic. The evidence reported punctually reflects the experience matured at our Institution, a comprehensive cancer centre, on the topic of interest.

COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience / Barba, M.; Krasniqi, E.; Pizzuti, L.; Mazzotta, M.; Marinelli, D.; Giuliano, G.; Di Liso, F. S.; Cappuzzo, F.; Landi, L.; Tomao, S.; Ciliberto, G.; Vici, P.. - In: THE BREAST JOURNAL. - ISSN 1075-122X. - 27:4(2021), pp. 359-362. [10.1111/tbj.14204]

COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience

Barba M.
Primo
;
Pizzuti L.;Mazzotta M.;Marinelli D.;Tomao S.
Ultimo
;
2021

Abstract

Substantial changes in the management of cancer patients have been required worldwide in response to the COVID-19 pandemic. Beyond the due details on the primitive cancer site and setting at diagnosis, these latter adaptions are most commonly exemplified by a significant reduction in the screening of asymptomatic subjects, delays in elective surgery and radiotherapy for primary tumors, and dose reductions and/or delays in systemic therapy administration. Advanced breast cancer patients with hormonal receptor positive, HER2 negative tumors are usually treated with endocrine therapy combined with CDK 4/6 inhibitors as first- and second-line treatment. During the pandemic, experts’ recommendations have suggested the omission or delay of CDK 4/6 inhibitors delivery, or a careful evaluation of their real need due to the hypothesized increased risk of SARS-Cov-2 infection and disease possibly related to neutropenia. The inherent literature is sparse and inconsistent. We herein present data on the use of CDK 4/6 inhibitors during the pandemic. The evidence reported punctually reflects the experience matured at our Institution, a comprehensive cancer centre, on the topic of interest.
2021
CDK4/6 inhibitors; covid-19; HR positive/HER2 negative metastatic breast cancer; COVID-19; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; female; humans; pandemics; protein kinase inhibitors; risk factors; breast neoplasms
01 Pubblicazione su rivista::01a Articolo in rivista
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience / Barba, M.; Krasniqi, E.; Pizzuti, L.; Mazzotta, M.; Marinelli, D.; Giuliano, G.; Di Liso, F. S.; Cappuzzo, F.; Landi, L.; Tomao, S.; Ciliberto, G.; Vici, P.. - In: THE BREAST JOURNAL. - ISSN 1075-122X. - 27:4(2021), pp. 359-362. [10.1111/tbj.14204]
File allegati a questo prodotto
File Dimensione Formato  
Barba_COVID‐19 risk_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 259.38 kB
Formato Adobe PDF
259.38 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1582769
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact